Eli Lilly & Co LLY Stock Forecast
AI-powered price prediction and analysis for Eli Lilly & Co · Alpha · vs marketSwitch to Total
See LLY's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Eli Lilly & Co
Eli Lilly & Co (LLY) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
- Eli Lilly reports earnings on Oct. 29. Here's why the Retatrutide story matters more than the quarter
- Eli Lilly expects up to $87 billion in 2026 revenue. Here's why the stock still looks undervalued.
- Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests
- Sign up free to read all 12 articles →
Where LLY sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| LLY Eli Lilly & Co | ▲ | $1.11T | 41.7x |
| JNJ Johnson & Johnson | ▼ | $635.56B | 30.2x |
| ONC Beone Medicines Ltd. | ▶ | $517.93B | – |
| ABBV Abbvie Inc. | ▼ | $484.61B | 76.8x |
| MRK Merck & Co., Inc. | ▼ | $358.85B | 113.1x |
| NVS Novartis Ag | ▼ | $274.47B | – |
| GSK Gsk Plc | ▼ | $202.48B | – |
| ABT Abbott Laboratories | ▶ | $178.85B | 28.6x |
| PFE Pfizer Inc | ▲ | $161.87B | 37.4x |
| VRTX Vertex Pharmaceuticals Inc / … | ▼ | $128.50B | 29.2x |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B | 12.5x |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $78.54B | 18.1x |
| SNY Sanofi | ▼ | $48.46B | – |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $47.98B | 67.9x |
| RPRX Royalty Pharma Plc | ▲ | $33.22B | 40.8x |
| ZTS Zoetis Inc. | ▼ | $31.26B | 12.0x |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B | – |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.72B | – |
| ZLAB Zai Lab Ltd | ▼ | $27.60B | – |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.74B | – |
| ROIV Roivant Sciences Ltd. | ▶ | $24.99B | – |
| UTHR United Therapeutics Corp | ▼ | $23.59B | 18.0x |
| INSM Insmed Inc | ▶ | $21.52B | – |
| VTRS Viatris Inc | ▶ | $20.15B | – |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $14.07B | 15.0x |
| ASND Ascendis Pharma A/S | ▶ | $13.83B | – |
| SMMT Summit Therapeutics Inc. | ▶ | $13.67B | – |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B | – |
| BBIO Bridgebio Pharma, Inc. | ▲ | $12.37B | – |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.37B | – |
| HCM Hutchmed (China) Ltd | ▶ | $11.93B | – |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B | – |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.79B | – |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.70B | – |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B | – |
| PTGX Protagonist Therapeutics, Inc | ▲ | $9.37B | – |
| CYTK Cytokinetics Inc | ▶ | $8.57B | – |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B | – |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B | – |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.57B | – |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.26B | – |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $7.02B | – |
| ABVX Abivax S.A. | ▼ | $6.83B | – |
| ALKS Alkermes Plc. | ▶ | $6.67B | – |
| LEGN Legend Biotech Corp | ▶ | $6.58B | – |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B | – |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.20B | 31.5x |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $6.18B | – |
| BLTE Belite Bio, Inc | ▲ | $5.97B | – |
| BLRX Biolinerx Ltd. | ▶ | $5.67B | – |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.59B | – |
| ERAS Erasca, Inc. | ▲ | $5.41B | – |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.25B | – |
| GPCR Structure Therapeutics Inc. | ▲ | $5.12B | – |
| MANE Veradermics, Inc | ▲ | $5.11B | – |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.90B | – |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B | – |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B | – |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B | – |
| INDV Indivior Pharmaceuticals, Inc. | ▲ | $4.26B | 12.0x |
FAQ
Is Eli Lilly & Co a good stock to buy?
Our AI analyzes Eli Lilly & Co daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Eli Lilly & Co predictions?
A per-ticker accuracy statistic for LLY is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Eli Lilly & Co forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Eli Lilly & Co? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.